14037-86-6Relevant articles and documents
Gallic acid acylated derivatives having anticancer activity and use thereof
-
, (2017/08/28)
The invention discloses gallic acid acylated derivatives having anticancer activity. The gallic acid acylated derivatives have a structural formula shown in the description. The acylated derivatives provided by the invention have good activity to oral cancer cells, have good selectivity and have a good clinical application value.
Dilazep analogues for the study of equilibrative nucleoside transporters 1 and 2 (ENT1 and ENT2)
Playa, Hilaire,Lewis, Timothy A.,Ting, Amal,Suh, Byung-Chul,Muoz, Benito,Matuza, Robert,Passer, Brent J.,Schreiber, Stuart L.,Buolamwini, John K.
supporting information, p. 5801 - 5804 (2015/01/08)
As ENT inhibitors including dilazep have shown efficacy improving oHSV1 targeted oncolytic cancer therapy, a series of dilazep analogues was synthesized and biologically evaluated to examine both ENT1 and ENT2 inhibition. The central diamine core, alkyl chains, ester linkage and substituents on the phenyl ring were all varied. Compounds were screened against ENT1 and ENT2 using a radio-ligand cell-based assay. Dilazep and analogues with minor structural changes are potent and selective ENT1 inhibitors. No selective ENT2 inhibitors were found, although some analogues were more potent against ENT2 than the parent dilazep.
